The Prognostic Value of the Systemic Inflammatory Score in Patients with Unresectable Metastatic Colorectal Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jun 22

PMID 29928454

Citations 8

Authors

Masatsune Shibutani

Kiyoshi Maeda

Hisashi Nagahara

Tatsunari Fukuoka

Shinji Matsutani

Kenjiro Kimura

Ryosuke Amano

Kosei Hirakawa

Masaichi Ohira

Affiliations

Soon will be listed here.

Abstract

Inflammation has been widely recognized as a contributor to cancer progression and several inflammatory markers have been reported as associated with the clinical outcomes in patients with various types of cancer. Recently, a novel inflammatory marker, the systemic inflammatory score (SIS), which is based on a combination of the lymphocyte-to-monocyte ratio (LMR) and the serum albumin concentration has been reported as a useful prognostic marker. The aim of the present study was to assess the prognostic value of the SIS in patients with unresectable metastatic colorectal cancer (mCRC). The retrospective cohort study included 160 patients who underwent combination chemotherapy for unresectable mCRC between January 2008 and December 2016. The SIS was used to classify the patients into three groups based on their LMR and the serum albumin concentration. Patients with high-LMR and high serum albumin level were given a score of 0; patients with low-LMR or low serum albumin level were given a score of 1; patients with low-LMR and low serum albumin level were given a score of 2. There were significant differences in the overall survival among the three SIS groups and the SIS was an independent prognostic factor for the overall survival. Although the SIS was significantly associated with the overall survival rate even when using the original cut-off values, the SIS according to the new cut-off values had a more accurate prognostic value. The present study determined that the SIS was a useful biomarker for predicting the survival outcomes in patients with unresectable mCRC, although the optimum cut-off value of the SIS according to the patients' background needs to be examined in further studies.

Citing Articles

The clinical value of nutritional and inflammatory indicators in predicting pneumonia among patients with intracerebral hemorrhage.

Zhao G, Chen Y, Gu Y, Xia X Sci Rep. 2024; 14(1):16171.

PMID: 39003396 PMC: 11246476. DOI: 10.1038/s41598-024-67227-y.

Preoperative Systemic Inflammation Score Predicts the Prognosis of Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy.

Wang Q, Ye J, Chen Z, Liao X, Wang X, Zhang C J Clin Med. 2024; 13(3).

PMID: 38337485 PMC: 10856497. DOI: 10.3390/jcm13030791.

Impact of Preoperative Nutritional Status on Long-term Survival in Patients With Stage I-III Colorectal Cancer.

Shibutani M, Kashiwagi S, Fukuoka T, Iseki Y, Kasashima H, Maeda K In Vivo. 2023; 37(4):1765-1774.

PMID: 37369485 PMC: 10347952. DOI: 10.21873/invivo.13265.

The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal Cancer.

Lisanti C, Basile D, Garattini S, Parnofiello A, Corvaja C, Cortiula F Cancers (Basel). 2023; 15(1).

PMID: 36612170 PMC: 9818397. DOI: 10.3390/cancers15010175.

Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome.

Galindo-Pumarino C, Collado M, Herrera M, Pena C Cancers (Basel). 2021; 13(5).

PMID: 33800796 PMC: 7961499. DOI: 10.3390/cancers13051130.

References

Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K . Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer. Oncol Lett. 2017; 13(2):1000-1006. PMC: 5351160. DOI: 10.3892/ol.2016.5487. View

Paik K, Lee I, Lee Y, Sung N, Kwon T . Clinical implications of systemic inflammatory response markers as independent prognostic factors in colorectal cancer patients. Cancer Res Treat. 2014; 46(1):65-73. PMC: 3918529. DOI: 10.4143/crt.2014.46.1.65. View

Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L . The origin and function of tumor-associated macrophages. Immunol Today. 1992; 13(7):265-70. DOI: 10.1016/0167-5699(92)90008-U. View

Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress A . Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res. 2013; 33(10):4591-4. View

Tanaka H, Muguruma K, Toyokawa T, Kubo N, Ohira M, Hirakawa K . Differential impact of the neutrophil-lymphocyte ratio on the survival of patients with stage IV gastric cancer. Dig Surg. 2014; 31(4-5):327-33. DOI: 10.1159/000369278. View

Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z . Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015; 113(4):626-33. PMC: 4647686. DOI: 10.1038/bjc.2015.241. View

McMillan D, Elahi M, Sattar N, Angerson W, Johnstone J, McArdle C . Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2002; 41(1-2):64-9. DOI: 10.1080/01635581.2001.9680613. View

Guo Y, Sun H, Zhang Y, Liao Z, Zhao L, Cui J . The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer: a meta-analysis. Oncotarget. 2017; 8(12):20011-20024. PMC: 5386740. DOI: 10.18632/oncotarget.15311. View

Eltohami Y, Kao H, Wei-Kai Lao W, Huang Y, Abdelrahman M, Liao C . The Prediction Value of the Systemic Inflammation Score for Oral Cavity Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2018; 158(6):1042-1050. DOI: 10.1177/0194599817751678. View

10.

Jia J, Zheng X, Chen Y, Wang L, Lin L, Ye X . Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer. Tumour Biol. 2015; 36(12):9319-25. DOI: 10.1007/s13277-015-3667-9. View

11.

Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y . A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res. 2013; 33(8):3291-4. View

12.

Dunn G, Old L, Schreiber R . The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2):137-48. DOI: 10.1016/j.immuni.2004.07.017. View

13.

Leek R, Harris A . Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002; 7(2):177-89. DOI: 10.1023/a:1020304003704. View

14.

Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008; 26(12):2006-12. DOI: 10.1200/JCO.2007.14.9898. View

15.

Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K . Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013; 14(13):1278-86. DOI: 10.1016/S1470-2045(13)70490-X. View

16.

Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y . The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 2012; 4(2):324-328. PMC: 3402729. DOI: 10.3892/ol.2012.722. View

17.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

18.

Ceze N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E . Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 2011; 68(5):1305-13. DOI: 10.1007/s00280-011-1610-3. View

19.

Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kondo T . Comparison of Preoperative Inflammation-based Prognostic Scores in Patients With Colorectal Cancer. Ann Surg. 2016; 267(3):527-531. DOI: 10.1097/SLA.0000000000002115. View

20.

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View